Adenosine kinase

Biochemical properties

AdK is a monomeric protein (~ 38-40 kDa), which works via an ordered Bi-Bi reaction mechanism. It belongs to the phosphofructokinase B (PfkB) family of sugar kinases. Other members of this family (also known as the RK family) include ribokinase (RK), inosine-guanosine kinase, fructokinase, and 1-phosphofructokinase. The members of the PfkB/RK family are identified by the presence of three conserved sequence motifs. The structures of AdK and several other PfK family of proteins have been determined from a number of organisms (see section below) Despite low sequence similarity between AdK and other PfkB family of proteins, these proteins are quite similar at structural levels. The AdK from mammalian sources, in addition to carrying out ATP-dependent phosphorylation of Ado, also catalyzes an Ado-AMP exchange reaction requiring ADP. This activity is an integral part of AdK and it presumably allows a rapid and precise control of Ado concentration in cells. The enzymatic activity of AdK from different sources show a marked dependence on phosphate (Pi) and/or pentavalent ions and it is a conserved property of the PfkB family of proteins. The conserved NXXE motif, which is a distinctive property of the PfkB family of proteins, is involved in Pi (PVI) dependency.

Evolution and Relationship to the PfkB Family of Proteins

The AdK gene/protein is mainly found in eukaryotic organisms Although a protein exhibiting AdK activity has been reported in Mycobacterium tuberculosis, sequence and biochemical characteristics of this enzyme reveal it to be an atypical enzyme that is more closely related to ribokinase and fructokinase (35%) than to other ADKs (less than 24%).

Gene and isoforms

The AdK gene in humans is located on chromosome 10 in the 10q11-10q24 region. In contrast to its coding sequence (about 1 Kb), the AdK gene in mammalian species is unusually large (~546 Kb in humans) and it consists of 11 exons (36 to 173 bp in length) and 10 introns whose lengths vary from 4.2 Kb to 128.6 Kb (average ~50Kb). The ratio of the non-coding to coding sequence for human ADK (550) is the highest known for any gene. The AdK gene in mammalian organisms is also linked in a head to head manner to the gene for the long isoform of AdK to the gene for μ3A adaptor protein, and both these genes are transcribed from a single bi-directional promoter. The large size of the AdK gene and its linkage to the gene for μ3A adaptor protein are apparently unique characteristic of the amniotes (e.g. various mammals, birds, and reptiles). In contrast, the AdK genes in other eukaryotic organisms are much smaller in lengths (1.3 – 20 Kb long). In mammals, two isoforms of Adk are present. These two isoforms show no difference in their biological activity and they differ only at the N-terminus where the long isoform (AdK-long) contains extra 21 amino acids that replace the first 4 amino acids of the short isoform (AdK-short). It was recently shown that of the two AdK isoforms, the AdK-long isoform is localized in the nucleus, whereas AdK-short is found in the cytoplasm.

Cardio- and neuro-protective roles

AdK plays a central role in controlling the cellular levels of Ado, which via its interaction with adenosine receptors in mammalian tissues produces a broad range of physiological responses including potent cardioprotective and neuroprotective activities. The overexpression of AdK in the brain, which leads to decreased Ado levels and loss of inhibition of neuronal excitability by astrocytes, has been proposed as the main underlying cause of progression of epilepsy. Hence, the modulation of AdK by external means provides an important strategy for harnessing its potential therapeutic benefits. As such, there is much interest in developing specific inhibitors of AdK. Many AdK inhibitors, some of which show useful analgesic, anti-seizure, and anti-inflammatory properties in animal models have been described.

Studies with mutant mammalian cells

In cultured mammalian cells, mainly Chinese hamster ovary (CHO) cells, many kinds of mutants that are affected in AdK and show interesting differences in their genetic and biochemical properties have been isolated; One kind of mutant that is obtained at unusually high spontaneous mutant frequency (10−3-10−4) contain large deletions within the AdK gene that leads to the loss of several introns and exons. Many mutants that are affected in the expression of either the expressions of the two AdK isoforms have also been isolated.

Inhibitors

• A-286501
• ABT-702
• GP3269

References

References

1. (February 1967). "Some properties of partially purified mammalian adenosine kinase". The Journal of Biological Chemistry.
2. (April 1951). "The enzymatic synthesis of adenylic acid; adenosinekinase". The Journal of Biological Chemistry.
3. (December 1951). "Enzymatic phosphorylation of adenosine and 2,6-diaminopurine riboside". The Journal of Biological Chemistry.
4. (1978). "The role of adenosine and 2'-deoxyadenosine in mammalian cells". Annual Review of Biochemistry.
5. (December 1977). "Role of S-adenosylhomocysteine in adenosinemediated toxicity in cultured mouse T lymphoma cells". Cell.
6. (May 2002). "Neonatal hepatic steatosis by disruption of the adenosine kinase gene". Proceedings of the National Academy of Sciences of the United States of America.
7. (September 2008). "Adenosine kinase and ribokinase--the RK family of proteins". Cellular and Molecular Life Sciences.
8. (2003). "Hyperhomocysteinemia and its role in the development of atherosclerosis". Clinical Biochemistry.
9. (May 1979). "S-adenosylhomocysteine toxicity in normal and adenosine kinase-deficient lymphoblasts of human origin". Proceedings of the National Academy of Sciences of the United States of America.
10. (October 2011). "Adenosine kinase deficiency disrupts the methionine cycle and causes hypermethioninemia, encephalopathy, and abnormal liver function". American Journal of Human Genetics.
11. (July 1994). "Kinetic studies of rat liver adenosine kinase. Explanation of exchange reaction between adenosine and AMP". The Journal of Biological Chemistry.
12. (April 1972). "Kinetic studies of adenosine kinase from Ehrlich ascites tumor cells". The Journal of Biological Chemistry.
13. (April 1987). "Adenosine kinase from human erythrocytes: kinetic studies and characterization of adenosine binding sites". Biochemistry.
14. (May 2000). "Crystal structures of Toxoplasma gondii adenosine kinase reveal a novel catalytic mechanism and prodrug binding". Journal of Molecular Biology.
15. (November 1998). "Structure of human adenosine kinase at 1.5 A resolution". Biochemistry.
16. (February 1996). "Cloning of human adenosine kinase cDNA: sequence similarity to microbial ribokinases and fructokinases". Proceedings of the National Academy of Sciences of the United States of America.
17. (February 1998). "Structure of Escherichia coli ribokinase in complex with ribose and dinucleotide determined to 1.8 A resolution: insights into a new family of kinase structures". Structure.
18. (October 1983). "Resistance to 9-beta-D-arabinofuranosyladenine in cultured leukemia L 1210 cells". Cancer Research.
19. (1989). "Drug Resistance in Mammalian Cells". CRC Press.
20. (March 1993). "Phosphorylation of adenosine in anoxic hepatocytes by an exchange reaction catalysed by adenosine kinase". The Biochemical Journal.
21. (June 1996). "Adenosine-AMP exchange activity is an integral part of the mammalian adenosine kinase". Biochemistry and Molecular Biology International.
22. (September 1978). "Activities and some properties of 5'-nucleotidase, adenosine kinase and adenosine deaminase in tissues from vertebrates and invertebrates in relation to the control of the concentration and the physiological role of adenosine". The Biochemical Journal.
23. (November 1995). "Production of adenosine and nucleoside analogs by the exchange reaction catalyzed by rat liver adenosine kinase". Biochemical Pharmacology.
24. (April 1996). "Pentavalent ions dependency of mammalian adenosine kinase". Biochemistry and Molecular Biology International.
25. (January 2000). "The influence of inorganic phosphate on the activity of adenosine kinase". Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology.
26. (July 2007). "Identification and characterization of human ribokinase and comparison of its properties with E. coli ribokinase and human adenosine kinase". FEBS Letters.
27. (November 2003). "Identification and characterization of a unique adenosine kinase from Mycobacterium tuberculosis". Journal of Bacteriology.
28. (1979). "Regional mapping, by exclusion, of adenosine kinase (ADK) on human chromosome 10 using the gene dosage approach". Cytogenet Cell Genet.
29. (January 2001). "Gene structure for adenosine kinase in Chinese hamster and human: high-frequency mutants of CHO cells involve deletions of several introns and exons". DNA and Cell Biology.
30. (March 2004). "Genomic organization and linkage via a bidirectional promoter of the AP-3 (adaptor protein-3) mu3A and AK (adenosine kinase) genes: deletion mutants of AK in Chinese hamster cells extend into the AP-3 mu3A gene". The Biochemical Journal.
31. (September 2004). "Molecular characterization of recombinant mouse adenosine kinase and evaluation as a target for protein phosphorylation". European Journal of Biochemistry.
32. (August 2000). "Structure-activity studies on mammalian adenosine kinase". Biochemical and Biophysical Research Communications.
33. (October 2009). "Subcellular localization of adenosine kinase in mammalian cells: The long isoform of AdK is localized in the nucleus". Biochemical and Biophysical Research Communications.
34. (January 1993). "Adenosine--a cardioprotective and therapeutic agent". Cardiovascular Research.
35. (February 1985). "The role of adenosine kinase in regulating adenosine concentration". The Biochemical Journal.
36. (February 2008). "Adenosine as a neuromodulator in neurological diseases". Current Opinion in Pharmacology.
37. (March 2008). "The adenosine kinase hypothesis of epileptogenesis". Progress in Neurobiology.
38. (February 2008). "Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice". The Journal of Clinical Investigation.
39. (February 2001). "Effects of A-134974, a novel adenosine kinase inhibitor, on carrageenan-induced inflammatory hyperalgesia and locomotor activity in rats: evaluation of the sites of action". The Journal of Pharmacology and Experimental Therapeutics.
40. (March 2000). "Therapeutic potential of adenosine kinase inhibitors". Expert Opinion on Investigational Drugs.
41. (2001). "Pyridopyrimidine analogues as novel adenosine kinase inhibitors.". Bioorg Med Chem Lett.
42. (June 2001). "Discovery of 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, an orally active, non-nucleoside adenosine kinase inhibitor". Journal of Medicinal Chemistry.
43. (November 1978). "Genetic and biochemical studies with the adenosine analogs toyocamycin and tubercidin: mutation at the adenosine kinase locus in Chinese hamster cells". Somatic Cell Genetics.
44. (April 1984). "Genetic and biochemical studies on mutants of CHO cells resistant to 7-deazapurine nucleosides: differences in the mechanisms of action of toyocamycin and tubercidin". Biochemical and Biophysical Research Communications.
45. (1986). "Purine and Pyrimidine Metabolism in Man V".